Multiple Myeloma | Oncology Today with Dr Neil Love: Key Presentations on the Treatment of Multiple Myeloma from the 2020 ASH Annual Meeting

1:10:31
 
Share
 

Manage episode 282748975 series 1464352
By Dr Neil Love. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Featuring an interview with Dr Sagar Lonial on the following topics:

  • Early versus late autologous stem cell transplant for newly diagnosed multiple myeloma (NDMM): Long-term follow-up analysis of the IFM 2009 trial
  • Updated analysis of the GRIFFIN trial: Daratumumab with lenalidomide, bortezomib and dexamethasone for transplant-eligible patients with NDMM
  • Phase III TOURMALINE-MM2 trial of oral ixazomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone for transplant-ineligible patients with NDMM
  • Phase III APOLLO study evaluating the addition of subcutaneous daratumumab to pomalidomide and dexamethasone for patients with relapsed/refractory (R/R) MM
  • Selinexor in combination with pomalidomide and dexamethasone for R/R MM
  • Interim analysis of the IKEMA trial evaluating depth of response and response kinetics with isatuximab/carfilzomib/dexamethasone for R/R MM
  • DREAMM-2: Single-agent belantamab mafodotin for patients with R/R MM; 1-year outcomes by prior therapy
  • DREAMM-6: Safety, tolerability and clinical activity of belantamab mafodotin in combination with bortezomib/dexamethasone for R/R MM
  • Updated results from the Phase I CRB-401 study investigating the B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel for R/R MM
  • CARTITUDE-1: A Phase IB/II study of the BCMA–directed CAR T-cell therapy ciltacabtagene autoleucel for R/R MM
  • Updated results from the Phase I CRB-402 study of the anti-BCMA CAR T-cell therapy bb21217 for R/R MM
  • Iberdomide in combination with dexamethasone and either daratumumab or bortezomib for patients with R/R MM
  • Updated results from the Phase I trial of teclistamab, a BCMA x CD3 bispecific antibody for R/R MM
  • Activity and safety of the bispecific antibodies talquetamab and BFCR4350A in patients with R/R MM
  • ANCHOR trial: Updated efficacy and safety data with melflufen in combination with dexamethasone and either daratumumab or bortezomib for R/R MM
  • KarMMa: Efficacy and safety of idecabtagene vicleucel in older patients with R/R MM
  • Assessment of minimal residual disease by next-generation sequencing and FDG-PET/CT for patients with R/R MM treated with venetoclax, carfilzomib and dexamethasone

CME information and select publications

2512 episodes